OnKure Therapeutics, Company Insiders
| OKUR Stock | 4.96 0.06 1.20% |
OnKure Therapeutics, employs about 14 people. The company is managed by 14 executives with a total tenure of roughly 0 years, averaging almost 0.0 years of service per executive, having 1.0 employees per reported executive. Discussion of OnKure Therapeutics,'s management performance can provide insight into the enterprise performance.
OnKure |
OnKure Therapeutics, Management Team Effectiveness
As of 03/10/2025, Total Assets is likely to drop to about 28.5 M. In addition to that, Non Current Assets Total is likely to drop to about 1.7 MOnKure Therapeutics,'s management efficiency ratios could be used to measure how well OnKure Therapeutics, manages its routine affairs as well as how well it operates its assets and liabilities.As of 03/10/2025, Common Stock Shares Outstanding is likely to drop to about 10.7 M
OnKure Therapeutics, Workforce Comparison
OnKure Therapeutics, is currently under evaluation in number of employees category among its peers. The total workforce of Biotechnology industry is now estimated at about 26,972. OnKure Therapeutics, adds roughly 0.0 in number of employees claiming only tiny portion of stocks in Biotechnology industry.
OnKure Therapeutics, Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific OnKure Therapeutics, insiders, such as employees or executives, is commonly permitted as long as it does not rely on OnKure Therapeutics,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, OnKure Therapeutics, insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Agresta Samuel over a month ago Acquisition by Agresta Samuel of 45000 shares of OnKure Therapeutics, at 5.19 subject to Rule 16b-3 | ||
Jansen Valerie Malyvanh over three months ago Acquisition by Jansen Valerie Malyvanh of 15300 shares of OnKure Therapeutics, at 18.2 subject to Rule 16b-3 | ||
Manke Isaac over three months ago Acquisition by Manke Isaac of 15300 shares of OnKure Therapeutics, at 18.2 subject to Rule 16b-3 | ||
Leonard Braden Michael over three months ago Acquisition by Leonard Braden Michael of 3457 shares of OKUR New subject to Rule 16b-3 | ||
Saccomano Nicholas A over three months ago Acquisition by Saccomano Nicholas A of 4556 shares of OnKure Therapeutics, subject to Rule 16b-3 |
OnKure Therapeutics, Notable Stakeholders
An OnKure Therapeutics, stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as OnKure Therapeutics, often face trade-offs trying to please all of them. OnKure Therapeutics,'s stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting OnKure Therapeutics,'s stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Nicholas Saccomano | CEO President | Profile | |
| Anthony Piscopio | President CoFounder | Profile | |
| Kevin Litwiler | Senior Pharmacology | Profile | |
| Jason CPA | Chief Officer | Profile | |
| Pr Liu | Member Board | Profile | |
| Rogan JD | General Secretary | Profile | |
| Roberta Alton | Senior Operations | Profile | |
| Dylan Hartley | Chief Officer | Profile | |
| Richard Woessner | Senior Pharmacology | Profile | |
| James Blake | Senior Discovery | Profile | |
| Rogan Nunn | General Secretary | Profile | |
| Duncan Walker | Chief Officer | Profile | |
| Mark Boys | Senior Chemistry | Profile | |
| MPH MD | Chief Officer | Profile |
About OnKure Therapeutics, Management Performance
The success or failure of an entity such as OnKure Therapeutics, often depends on how effective the management is. OnKure Therapeutics, management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of OnKure management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the OnKure management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
OnKure Therapeutics, is entity of United States. It is traded as Stock on NASDAQ exchange.
OnKure Therapeutics, Workforce Analysis
Traditionally, organizations such as OnKure Therapeutics, use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare OnKure Therapeutics, within its industry.OnKure Therapeutics, Manpower Efficiency
Return on OnKure Therapeutics, Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 2.5M | |
| Net Loss Per Executive | 2.5M | |
| Working Capital Per Employee | 1.9M | |
| Working Capital Per Executive | 1.9M |
Additional Tools for OnKure Stock Analysis
When running OnKure Therapeutics,'s price analysis, check to measure OnKure Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OnKure Therapeutics, is operating at the current time. Most of OnKure Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of OnKure Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OnKure Therapeutics,'s price. Additionally, you may evaluate how the addition of OnKure Therapeutics, to your portfolios can decrease your overall portfolio volatility.